Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference
Silence Therapeutics (Nasdaq: SLN), a global clinical stage biotechnology company focused on developing precision engineered medicines that silence diseases, has announced its participation in an upcoming fireside chat at the Jefferies London Healthcare Conference. The event is scheduled for Wednesday, November 20th at 2:00 p.m. GMT.
Interested parties can access the live webcast through the Investors section of Silence's website, with an archived replay available after the conference.
Silence Therapeutics (Nasdaq: SLN), una società biotecnologica globale in fase clinica focalizzata sullo sviluppo di medicinali ingegnerizzati di precisione per silenziare le malattie, ha annunciato la sua partecipazione a un prossimo fireside chat durante il Jefferies London Healthcare Conference. L'evento è in programma per mercoledì 20 novembre alle 14:00 GMT.
Le parti interessate possono accedere alla trasmissione in diretta attraverso la sezione Investitori del sito web di Silence, con una riproduzione archiviata disponibile dopo la conferenza.
Silence Therapeutics (Nasdaq: SLN), una compañía biotecnológica global en etapa clínica enfocada en desarrollar medicamentos de precisión diseñados para silenciar enfermedades, ha anunciado su participación en un próximo fireside chat en la Jefferies London Healthcare Conference. El evento está programado para el miércoles 20 de noviembre a las 14:00 GMT.
Las partes interesadas pueden acceder a la transmisión en vivo a través de la sección de Inversores del sitio web de Silence, con una repetición archivada disponible después de la conferencia.
Silence Therapeutics (Nasdaq: SLN)은 질병을 침묵시키는 정밀하게 조정된 의약품 개발에 중점을 둔 글로벌 임상 단계 생명공학 회사로, Jefferies London Healthcare Conference에서 열리는 fireside chat에 참가한다고 발표했습니다. 이 행사는 11월 20일 수요일 오후 2시 GMT로 예정되어 있습니다.
관심 있는 분들은 Silence 웹사이트의 투자자 섹션을 통해 실시간 웹캐스트에 접속할 수 있으며, 회의 후 아카이브된 재생도 제공됩니다.
Silence Therapeutics (Nasdaq: SLN), une entreprise biopharmaceutique mondiale en phase clinique spécialisée dans le développement de médicaments de précision qui silencent les maladies, a annoncé sa participation à un prochain fireside chat lors de la Jefferies London Healthcare Conference. L'événement est prévu pour le mercredi 20 novembre à 14h00 GMT.
Les parties intéressées peuvent accéder au webinaire en direct via la section Investisseurs du site web de Silence, avec une rediffusion archivée disponible après la conférence.
Silence Therapeutics (Nasdaq: SLN), ein globales biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung präzisionsgefertigter Medikamente zur Bekämpfung von Krankheiten spezialisiert hat, gab seine Teilnahme an einem bevorstehenden Fireside Chat auf der Jefferies London Healthcare Conference bekannt. Die Veranstaltung ist für Mittwoch, den 20. November um 14:00 Uhr GMT angesetzt.
Interessierte können über den Investorensektor der Website von Silence auf das Live-Webcast zugreifen, mit einer archivierten Wiedergabe, die nach der Konferenz verfügbar ist.
- None.
- None.
The live webcast can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available following the conference.
About Silence Therapeutics
Silence Therapeutics is a global clinical stage biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD™ platform to create innovative siRNAs designed to precisely target and silence disease associated genes in the liver, which represents a substantial opportunity. Silence focuses on areas of high unmet medical need with programs advancing in cardiovascular disease, hematology and rare diseases. Silence also maintains research and development collaborations with AstraZeneca and Hansoh Pharma, among others. For more information, please visit https://www.silence-therapeutics.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241113003941/en/
Silence Therapeutics plc
Gem Hopkins, VP, Head of IR and Corporate Communications
ir@silence-therapeutics.com
Tel: +1 (646) 637-3208
Source: Silence Therapeutics plc
FAQ
When is Silence Therapeutics (SLN) presenting at the Jefferies London Healthcare Conference?
How can investors watch Silence Therapeutics' (SLN) Jefferies Conference presentation?
What type of presentation will Silence Therapeutics (SLN) give at the Jefferies Conference?
